CA2230690A1 - Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments - Google Patents

Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments

Info

Publication number
CA2230690A1
CA2230690A1 CA002230690A CA2230690A CA2230690A1 CA 2230690 A1 CA2230690 A1 CA 2230690A1 CA 002230690 A CA002230690 A CA 002230690A CA 2230690 A CA2230690 A CA 2230690A CA 2230690 A1 CA2230690 A1 CA 2230690A1
Authority
CA
Canada
Prior art keywords
pain
administration
ketamine
transmucosal
management
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002230690A
Other languages
English (en)
Other versions
CA2230690C (fr
Inventor
Stuart L. Weg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2230690A1 publication Critical patent/CA2230690A1/fr
Application granted granted Critical
Publication of CA2230690C publication Critical patent/CA2230690C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002230690A 1995-08-30 1996-08-29 Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments Expired - Fee Related CA2230690C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US294695P 1995-08-30 1995-08-30
US60/002,946 1995-08-30
PCT/US1996/014095 WO1997007750A1 (fr) 1995-08-30 1996-08-29 Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments

Publications (2)

Publication Number Publication Date
CA2230690A1 true CA2230690A1 (fr) 1997-03-06
CA2230690C CA2230690C (fr) 2008-12-23

Family

ID=21703322

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002230690A Expired - Fee Related CA2230690C (fr) 1995-08-30 1996-08-29 Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments

Country Status (3)

Country Link
JP (2) JPH11511466A (fr)
CA (1) CA2230690C (fr)
WO (1) WO1997007750A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1103256A1 (fr) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Utilisation de la kétamine pour le traitement de la dysfonction immunitaire neuroendocrine et du psyhosyndrome algogénique
DE10025946A1 (de) * 2000-05-26 2001-11-29 Gruenenthal Gmbh Wirkstoffkombination
KR20030034171A (ko) 2001-07-06 2003-05-01 엔도 파마슈티걸즈, 인크. 옥시모르폰 제어 방출 제형
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
NZ540282A (en) * 2002-11-18 2008-06-30 Yaupon Therapeutics Inc Analgesic uses of norketamine and ketamine/norketamine prodrugs
WO2004087209A1 (fr) * 2003-03-27 2004-10-14 Hisamitsu Pharmaceutical Co., Inc. Preparation pour assurer une concentration sanguine therapeutiquement efficace d'un potentialisateur d'activite analgesique
CN104395283A (zh) * 2011-10-14 2015-03-04 美国政府健康及人类服务部 (2r,6r)-羟基去甲氯胺酮、(s)-脱氢去甲氯胺酮以及(r,s)-氯胺酮的其他立体异构脱氢和羟基化代谢物在治疗忧郁症和神经性疼痛中的应用
WO2014020155A1 (fr) * 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Formes d'administration transmuqueuse orale de kétamine s
EP3636251B1 (fr) 2013-03-15 2022-01-19 Janssen Pharmaceutica NV Composition pharmaceutique de hydrochlorure s-kétamine
JP2017528483A (ja) 2014-09-15 2017-09-28 ヤンセン ファーマシューティカ エヌ．ベー． Ｖａｌ６６Ｍｅｔ（ＳＮＰ ｒｓ６２６５）遺伝子型特異的投薬レジメン及びうつ病の治療のための方法
US11191734B2 (en) * 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US9963435B2 (en) 2016-08-31 2018-05-08 Dart Neuroscience, Llc Compounds for therapeutic use
JP7069295B2 (ja) 2017-08-17 2022-05-17 エックスダブリューファルマ リミテッド 活性酸素種スカベンジャー誘導体の調製および使用
JP6976618B2 (ja) 2017-09-04 2021-12-08 エックスダブリューファルマ リミテッド 活性酸素種スカベンジャーの調製および使用
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US11707440B2 (en) 2017-12-22 2023-07-25 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
CA3087912C (fr) * 2018-01-10 2023-03-14 Xw Laboratories Inc. Promedicaments a base de ketamine, compositions et utilisations de ceux-ci
WO2020178653A1 (fr) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Eskétamine pour le traitement de la dépression
TWI844074B (zh) 2021-08-13 2024-06-01 凱瑞康寧生技股份有限公司 氯胺酮衍生物之醫藥組成物及口服劑型

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
CA2115792C (fr) * 1993-03-05 2005-11-01 David J. Mayer Methode de traitement de la douleur
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain

Also Published As

Publication number Publication date
WO1997007750A1 (fr) 1997-03-06
JPH11511466A (ja) 1999-10-05
CA2230690C (fr) 2008-12-23
JP2009073842A (ja) 2009-04-09

Similar Documents

Publication Publication Date Title
CA2230690A1 (fr) Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments
CA2184077A1 (fr) Administration nasale et oculaire de ketamine pour le traitement de la douleur et les desintoxications
EP0831848A4 (fr) Procede de traitement de maladies pulmonaires au moyen d'oligonucleotides antisens
EP0831832A4 (fr) Procedes pour lutter contre des maladies infectieuses a l'aide de bis-benzimidazoles dicationiques
EP1514105A4 (fr) Procedes de modulation de l'activite de la tubuline desacetylase
CZ176495A3 (en) The use of riluzol for preparing a medicament suitable for treating parkinson's disease and parkinson's syndromes
AU5881894A (en) Pharmaceutical composition for treating nicotine dependence
WO2003092617A3 (fr) Combinaisons destinees au traitement de troubles cutanes inflammatoires
CA2150185A1 (fr) Traitement des affections inflammatoires stoma-peripheriques
MXPA04003548A (es) Tratamiento de neumonia severa mediante administracion de inhibidor de via factor de tejido.
CA2253130A1 (fr) Medicament pour traiter l'obesite et ameliorer le metabolisme lipidique
Hay et al. Short course ketoconazole therapy in pityriasis versicolor
WO2004050025A3 (fr) Methode de traitement de la douleur aigue au moyen d'une forme posologique unitaire contenant de l'ibuprofene et de l'oxycodone
HUT68171A (en) Preparations containing 4-aminopyridine for the treatment of neurological conditions
CA2403994A1 (fr) Administration nasale d'agents pour traiter la gastroparesie
Zachariae et al. Ciclosporin A in acrodermatitis continua
EP0744176A3 (fr) Médicaments pour inhiber les pertes osseuses
MD970254A (en) Use of melatonine for treatment of patients having a medicamental dependence
WO1990001321A3 (fr) Procede de traitement et de prevention de la perte de masse osseuse
AU7639796A (en) Novel drug for relieving pain and promoting the removal of calculi in urolithiasis
WO2002089848A3 (fr) Methode de traitement du diabete
Nelson et al. An evaluation of the analgesic efficacy of diclofenac potassium, aspirin, and placebo in postoperative dental pain
CA2403674A1 (fr) Utilisation de triiodothyronine pour le traitement de l'insuffisance cardiaque congestive
WO2001000191A3 (fr) Utilisation de fosphenytoine pour le traitement de douleur neuropathique aigue
UA22191A (uk) Спосіб корекції моторhої фуhкції шлуhка і дваhадцятіпалої кишки після резекції шлуhка і ваготомії

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140829